Greenwich LifeSciences (NASDAQ: GLSI) CEO and CFO reports 2,900-share purchase
Rhea-AI Filing Summary
Greenwich LifeSciences insider activity: Snehal Patel, who serves as CEO, CFO, director and a 10% owner of Greenwich LifeSciences, Inc., reported buying additional company stock. On 01/12/2026, he purchased 2,900 shares of common stock in an open market transaction coded as a "P" transaction at a price of $27.54 per share.
Following this purchase, Patel directly beneficially owned 5,602,302 shares of Greenwich LifeSciences common stock. The filing reflects direct ownership, with no indirect ownership reported in this transaction.
Positive
- None.
Negative
- None.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Purchase | Common Stock | 2,900 | $27.54 | $80K |
AI-generated analysis. How Rhea-AI works. Not financial advice.
FAQ
What insider transaction did GLSI report in this Form 4?
The Form 4 reports that Snehal Patel, an insider of Greenwich LifeSciences, Inc., purchased shares of the company’s common stock in a direct ownership transaction.
What is Snehal Patel’s role at Greenwich LifeSciences (GLSI)?
Snehal Patel is a director, a 10% owner, and also serves as the company’s CEO and CFO.
Was the GLSI insider transaction reported as direct or indirect ownership?
The transaction was reported as direct ownership (D), with no nature of indirect beneficial ownership listed.
What does transaction code "P" mean in this GLSI Form 4?
The transaction code "P" indicates a purchase of common stock, typically in an open market transaction.